Gempharmatech Co. Ltd. A Total Liabilities

Latest as of June 2025: CN¥630.58 Million CNY ≈ $92.27 Million USD

Gempharmatech Co. Ltd. A total liabilities. Based on the latest financial reports, Gempharmatech Co. Ltd. A (688046) has total liabilities worth CN¥630.58 Million CNY (≈ $92.27 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Gempharmatech Co. Ltd. A's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Gempharmatech Co. Ltd. A (2019–2024)

Total liabilities of Gempharmatech Co. Ltd. A from 2019 to 2024. This chart illustrates how Gempharmatech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data.

Gempharmatech Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Gempharmatech Co. Ltd. A ranked by their total liabilities.

Company	Country	Total Liabilities
Dalrymple Bay Infrastructure Ltd AU:DBI	Australia	AU$2.51 Billion
HCI Group Inc NYSE:HCI	USA	$1.43 Billion
Geo Group Inc NYSE:GEO	USA	$2.34 Billion
Far Eastern International Bank TW:2845	Taiwan	NT$828.52 Billion
Driven Brands Holdings Inc NASDAQ:DRVN	USA	$2.71 Billion
Woolworths Holdings Ltd JSE:WHL	South Africa	ZAC30.14 Billion
Zhejiang DiAn Diagnostics Co SHE:300244	China	CN¥5.41 Billion
Grupo Bafar S.A.B. de C.V MX:BAFARB	Mexico	MX$16.53 Billion

Liability Composition Analysis (2019–2024)

This chart breaks down Gempharmatech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Gempharmatech Co. Ltd. A.

Liquidity & Leverage Metrics

Gempharmatech Co. Ltd. A Total Liabilities Ratios Explained

Gempharmatech Co. Ltd. A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.29	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.23	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Gempharmatech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Gempharmatech Co. Ltd. A (2019–2024)

The table below shows the annual total liabilities of Gempharmatech Co. Ltd. A from 2019 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥437.92 Million ≈ $64.08 Million	-3.31%
2023-12-31	CN¥452.93 Million ≈ $66.28 Million	+64.10%
2022-12-31	CN¥276.00 Million ≈ $40.39 Million	+2.69%
2021-12-31	CN¥268.78 Million ≈ $39.33 Million	+18.95%
2020-12-31	CN¥225.95 Million ≈ $33.06 Million	+53.02%
2019-12-31	CN¥147.66 Million ≈ $21.61 Million	--

About Gempharmatech Co. Ltd. A

SHG:688046 China Biotechnology

Market Cap

$1.96 Billion

CN¥13.41 Billion CNY

Market Cap Rank

#6013 Global

#1124 in China

Share Price

CN¥32.70

Change (1 day)

-1.95%

52-Week Range

CN¥13.04 - CN¥40.95

All Time High

CN¥40.95